Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Phathom Pharmaceuticals, Inc. - Common Stock
(NQ:
PHAT
)
15.71
-0.88 (-5.30%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Phathom Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
PHATHOM PHARMACEUTICALS INC (NASDAQ:PHAT) Shows Strong Growth and Momentum Alignment with Minervini Strategy
↗
December 13, 2025
PHAT stock aligns with the Minervini growth strategy, showing a strong technical uptrend and explosive 460% revenue growth, making it a high-potential momentum candidate.
Via
Chartmill
High Growth Momentum and Technical Strength Drive PHATHOM PHARMACEUTICALS INC (NASDAQ:PHAT)
↗
November 14, 2025
Discover a powerful stock-picking strategy combining Minervini's Trend Template with High Growth Momentum to find high-potential stocks like PHAT.
Via
Chartmill
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
November 04, 2025
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
November 03, 2025
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Earnings Scheduled For October 30, 2025
↗
October 30, 2025
Via
Benzinga
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Phathom Pharmaceuticals (NASDAQ:PHAT) Surpasses Q3 2025 Earnings Estimates and Raises Full-Year Guidance
↗
October 30, 2025
Phathom Pharma's Q3 2025 earnings beat expectations. Revenue hit $49.5M, and its EPS loss narrowed to $0.15. The company also raised its full-year 2025 revenue guidance.
Via
Chartmill
Topics
Earnings
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
October 30, 2025
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
October 25, 2025
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
October 23, 2025
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
October 20, 2025
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
October 06, 2025
From
Phathom Pharmaceuticals
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
October 01, 2025
Via
Benzinga
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
August 25, 2025
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing
August 20, 2025
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom (PHAT) Q2 Revenue Jumps 441%
↗
August 07, 2025
Via
The Motley Fool
Phathom Pharmaceuticals (NASDAQ:PHAT) Surpasses Q2 Estimates with Strong VOQUEZNA Growth, Shares Jump 6% in Premarket
↗
August 07, 2025
Phathom Pharmaceuticals (PHAT) beats Q2 revenue and EPS estimates, driven by strong VOQUEZNA adoption. Shares rise 6.2% premarket as company narrows losses and raises full-year guidance.
Via
Chartmill
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 07, 2025
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
July 28, 2025
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 23, 2025
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
June 23, 2025
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
June 16, 2025
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday
↗
June 13, 2025
Via
Benzinga
Phathom Pharmaceuticals Stock Doubles After FDA Grants Full 10-Year Exclusivity For Voquezna
↗
June 06, 2025
Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) shares are trading lower Friday after the company announced a major regulatory win.
Via
Benzinga
Which stocks are moving on Friday?
↗
June 06, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.
Via
Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
↗
June 06, 2025
Via
Benzinga
Let's take a look at the stocks that are in motion in today's session.
↗
June 06, 2025
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via
Chartmill
Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
June 06, 2025
From
Phathom Pharmaceuticals
Via
GlobeNewswire
Palo Alto Networks, Take-Two Interactive Software, VF Corp And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
May 21, 2025
Via
Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
↗
May 16, 2025
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
